Biogazelle, a Ghent, Belgium-based provider of expert laboratory services in the area of gene expression analysis, raises €2.0m in Series B funding.
Backers included QBIC Arkiv Fund, Foundation Majoie and SOFI.
The company intends to use the funds to further develop its research on therapeutic RNA targets for specific cancer types, and to expand its commercial activities.
Founded in 2007 as Ghent University spin-off by Jan Hellemans, CEO, and Jo Vandesompele, CSO, Biogazelle leverages RNA sequencing, digital PCR and software tools to offer laboratory services for gene expression analysis.
FinSMEs
10/10/2014